Osteoprotegerin mitigates tail suspension-induced osteopenia.
The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.
Abstract
Osteoprotegerin (OPG) is a recently discovered protein related to the tumor necrosis factor receptor family. It has been shown to inhibit ovariectomy (ovx)-induced resorption in rats and increase bone mineral density in young mice. Tail suspension is a procedure that inhibits bone formation in maturing rodents. This study was designed to quantify OPG's effect on cortical bone formation. Fifty-four mice were assigned to one of five groups (n = 10-11/group). A baseline control group was killed on day 0 of the 10 day study. The remaining groups were: vivarium housed (nonsuspended) control mice receiving 0.3 mg/kg per day OPG; vivarium control mice receiving daily placebo injections; tail-suspended mice receiving 0. 3 mg/kg per day OPG; and tail-suspended mice receiving placebo injections. Tetracycline was administered on days 0 and 8. OPG treatment of tail-suspended mice produced mechanical properties similar to those of placebo-treated, vivarium-housed mice: structural stiffness (8.5%, 20.7%) and elastic (13.9%, 10.1%) and maximum (4.7%, 8.1%) force were increased compared with placebo controls (vivarium, suspended groups). Percent mineral composition was highly significantly greater (p < 0.001 for all comparisons) for OPG-treated mice in the femur, tibia, and humerus, relative to placebo treatment. Matrix mass was also significantly increased in the femur, although not to the same degree as mineral mass. OPG decreased the amount of femoral endocortical resorption compared with…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“OPG had no influence on longitudinal bone growth in normal young rats (185), mice (186), piglets (187), or cynomolgus monkeys (25).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [186]
In the citing paper
“OPG preserved bone mass and increased cortical bone strength in tail-suspended mice (186).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [186]
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439 · cited 1×
“A polypeptide ligand for OPG (OPGL) activates mature osteoclasts and modulates osteoclast differentiation from marrow-derived precursors in conjunction with macrophage colony stimulating factor (M-CSF).(15) OPGL increases the size of osteoclasts cultured with M-CSF, and OPG blocks this activity in vitro.”
BackgroundSelf-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · cited 3×
“This suggests a mechanism possibly unrelated to the previously reported inhibition of resorption.(21) The increase in bone mass contributed to an OPG-induced increase in femoral mechanical properties.”
BackgroundMethodResultInfluentialSelf-citationParfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Bone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483 · cited 3×
“By 2 months of age, histological examination of the metaphysis at the proximal tibia and distal femur revealed almost no trabeculae.(3,17) OPG inhibits osteoclastogenesis and tartrate-resistant acid phosphatase (TRAP) in vitro in a dose-dependent manner(21) by interrupting cell-to-cell interaction(32); moreover, it de…”
BackgroundSelf-citationYasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201 · cited 1×
“OPG inhibits osteoclastogenesis and tartrate-resistant acid phosphatase (TRAP) in vitro in a dose-dependent manner(21) by interrupting cell-to-cell interaction(32); moreover, it decreases osteoclast lifespan and increases osteoclast apoptosis.(1,32) OPG has been demonstrated to be expressed by osteoblasts,(18) and thi…”
BackgroundSevere osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775 · cited 2×
“By 2 months of age, histological examination of the metaphysis at the proximal tibia and distal femur revealed almost no trabeculae.(3,17) OPG inhibits osteoclastogenesis and tartrate-resistant acid phosphatase (TRAP) in vitro in a dose-dependent manner(21) by interrupting cell-to-cell interaction(32); moreover, it de…”
BackgroundYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Cited by 650
Hofbauer, L. C., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., & Khosla, S. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9394 · Cited by 311
Self-citation
Research works printed but not linked: 7
- Dempster, 1998, Effects of osteoprotegerin on human and rat osteoclasts, Bone, 23, S432
- Ferguson, 1997, Effects of tail suspension and insulin-like growth factor-1 on mouse bone mechanical properties, Grav Space Biol Bul, 11, 17
- Hofbauer, 1998, Estrogen stimulates production of anti-resorptive cytokine receptor osteoprotegerin in human osteoblastic cells, Bone, 23, S172
- Ohlsson, 1998, Osteoprotegerin mRNA expression in human osteoblast-like cells, Bone, 23, S529
- Shalhoub, 1998, Characterization of OPGL-induced osteoclast formation from peripheral bood mononuclear cell precursors, Bone, 23, S217
- Wronski, 1983, Effects of spaceflight on periosteal bone formation in rats, Am J Phys, 244, R305
- Yasuda, 1998, Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG), Endocrinology, 139, 1329, 10.1210/en.139.3.1329 · DOI · Paper page
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586
“loss associated with immobilization in animals [134].”
Mechanical Signaling for Bone Modeling and Remodeling
Robling, A. G., & Turner, C. H. (2009) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v19.i4.50 · Cited by 422
Romas, E., Gillespie, M. T., & Martin, T. J. (2002) · Bone · doi:10.1016/s8756-3282(01)00682-2 · Cited by 411
Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D.
Price, P. A., June, H. H., Buckley, J. R., & Williamson, M. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1001.097102 · Cited by 376
Metadata
- Authors
- Bateman, T. A., Dunstan, C. R., Ferguson, V. L., Lacey, D. L., Ayers, R. A., & Simske, S. J.
- Affiliations
- University of Colorado Boulder (US)
- Amgen (United States) (US)
- Corresponding author
- Bateman, T.A.
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2000-05
- Volume
- 26
- Issue
- 5
- Pages
- 443-449
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W2143822364
- Cited by
- 66
- References
- 33
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 1 · 2016: 1 · 2015: 1 · 2014: 1 · 2013: 3
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Bone (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Physiology (medical) › Spaceflight effects on biology
- Keywords
- osteoprotegerin, tail suspension test, osteopenia, bone formation, bone resorption, cortical bone, bone mineral density, bone mechanical properties, RANKL inhibition
- MeSH terms
- Animals, Bone Diseases, Metabolic, Glycoproteins, Male, Mice, Inbred C57BL, Placebos, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Hindlimb Suspension, Mice, Rats, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Osteoprotegerin mitigates tail suspension-induced osteopenia. https://app.cochat.ai/papers/10.1016/s8756-3282(00)00256-8
- The paper
- Bateman, T. A., Dunstan, C. R., Ferguson, V. L., Lacey, D. L., Ayers, R. A., & Simske, S. J. (2000). Osteoprotegerin mitigates tail suspension-induced osteopenia. Bone. https://doi.org/10.1016/s8756-3282(00)00256-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.